|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
69,020,000 |
Market
Cap: |
106.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6003 - $4.53 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile NGM Biopharmaceuticals is a biopharmaceutical company. Co. has five product candidates in the clinic, three wholly-owned by Co. (NGM707, NGM120 and aldafermin), one being progressed by its collaborator, Merck Sharp & Dohme Corp., or Merck (MK-3655) and one optionable by Merck (NGM621). Co.'s oncology product candidates include NGM707, NGM831, NGM438 and NGM120 and their related compounds. NGM621 was engineered to bind to, and be a long-acting inhibitor of, complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, secondary to age-related macular degeneration. MK-3655 isin Phase 2b development for the treatment of nonalcoholic steatohepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
94,704 |
94,704 |
9,606,382 |
Total Buy Value |
$0 |
$64,854 |
$64,854 |
$87,820,003 |
Total People Bought |
0 |
4 |
4 |
5 |
Total Buy Transactions |
0 |
10 |
10 |
130 |
Total Shares Sold |
0 |
0 |
0 |
85,082 |
Total Sell Value |
$0 |
$0 |
$0 |
$438,308 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Goeddel David V |
Director |
|
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
2.25 |
37% |
|
Column Group Ii Gp, Lp |
10% Owner |
|
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
1.5 |
37% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
1.42 |
-2% |
|
Column Group Ii Gp, Lp |
10% Owner |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
1.42 |
-2% |
|
Goeddel David V |
Director |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
2.17 |
-2% |
|
Tcg Iv Gp, Llc |
10% Owner |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
1.42 |
-8% |
|
Column Group Ii Gp, Lp |
10% Owner |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
1.42 |
-8% |
|
Goeddel David V |
Director |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
2.17 |
-8% |
|
Woodhouse David J |
Chief Executive Officer |
|
2021-12-29 |
4 |
OE |
$7.70 |
$137,989 |
D/D |
17,654 |
17,654 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-12-07 |
4 |
AS |
$18.60 |
$279,000 |
D/D |
(15,000) |
908,893 |
|
-13% |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-12-06 |
4 |
OE |
$1.44 |
$99,999 |
D/D |
69,444 |
923,893 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-12-06 |
4 |
AS |
$18.21 |
$273,150 |
D/D |
(15,000) |
854,449 |
|
-17% |
|
Woodhouse David J |
Chief Executive Officer |
|
2021-11-18 |
4 |
AS |
$20.02 |
$300,300 |
D/D |
(15,000) |
0 |
|
-13% |
|
Woodhouse David J |
Chief Executive Officer |
|
2021-11-18 |
4 |
OE |
$7.54 |
$113,100 |
D/D |
15,000 |
15,000 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-11-15 |
4 |
AS |
$19.56 |
$591,750 |
D/D |
(30,000) |
869,449 |
|
-19% |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-10-12 |
4 |
AS |
$20.14 |
$302,100 |
D/D |
(15,000) |
899,449 |
|
-30% |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-10-11 |
4 |
AS |
$20.41 |
$306,150 |
D/D |
(15,000) |
914,449 |
|
-27% |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2021-10-05 |
4 |
AS |
$22.00 |
$44,000 |
D/D |
(2,000) |
0 |
|
-26% |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2021-10-05 |
4 |
OE |
$12.06 |
$24,120 |
D/D |
2,000 |
2,000 |
|
- |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-09-14 |
4 |
AS |
$25.54 |
$384,892 |
D/D |
(15,000) |
929,449 |
|
-43% |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-09-13 |
4 |
AS |
$25.59 |
$390,414 |
D/D |
(15,000) |
944,449 |
|
-44% |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2021-08-12 |
4 |
S |
$23.50 |
$188,000 |
D/D |
(8,000) |
0 |
|
20% |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2021-08-12 |
4 |
OE |
$12.06 |
$96,480 |
D/D |
8,000 |
8,000 |
|
- |
|
Lieu Hsiao |
SVP, Chief Medical Officer |
|
2021-08-11 |
4 |
S |
$23.00 |
$51,934 |
D/D |
(2,258) |
0 |
|
19% |
|
Chen Jin-Long |
Chief Scientific Officer |
|
2021-08-10 |
4 |
AS |
$23.15 |
$347,250 |
D/D |
(15,000) |
959,449 |
|
-20% |
|
154 Records found
|
|
Page 6 of 7 |
|
|